Review Article
Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis
Table 3
Summary of inhaled colistin trials.
| Author | Study design | Subjects | Dose used | Outcomes | Main results |
| Jensen et al. [17] | RCT | . Age = 7–35 years. Inclusion criteria: chronic P. aeruginosa infection | Colistin (1 million units) BID for 3 months | Lung function (FEV1 and FVC) and clinical score | Significant improvement in clinical symptom score and pulmonary function |
| Day et al. [18] | Crossover study | . Age = 5–16 years. Inclusion criteria: chronic P. aeruginosa infection | Colistin (1 million units) BID for 3 months | Lung function (FEV1 and FVC), antibiotic use and hospital admissions, and symptom score | Significantly improved FEV1, FVC. Decreased antibiotic use and hospitalization, and decreased symptom score |
| Nikonova et al. [19] | Prospective study | . Age = ≤5 years. Inclusion criteria: chronic P. aeruginosa infection | Colistin (1 million units) BID for 3 weeks, followed till 1 year | Exacerbation rate, pulmonary symptoms | Significant improvement in the symptoms and reduced exacerbation |
|
|